Piramal

Piramal Pharma Solutions names John Fowler COO

Tuesday, September 12, 2017

Piramal Pharma Solutions (PPS), part of Piramal Enterprises Limited, announce the appointment of John Fowler as its Chief Operating Officer. PPS is a leader in Integrated Contract Development and Manufacturing, with a global network of 12 development and manufacturing facilities across North America, Europe and Asia. PPS offers a comprehensive range of services including Drug Discovery Solutions, Process & Pharmaceutical Development services, Clinical Trial Supplies and Commercial supply of APIs and Finished dosage forms. As Chief Operating Officer, John will be responsible for Global Operations and Research & Development (R&D), and will play a lead role in ensuring that our customers consistently experience differentiated and excellent levels of service.

[Read More]

AC Immune, Piramal Imaging ink agreement for Alzheimer’s disease

Thursday, May 15, 2014

AC Immune, a Swiss-based biopharmaceutical company, and Piramal Imaging, a division of Piramal Enterprises, have entered into an exclusive worldwide license agreement for the research, development and commercialization of AC Immune’s Tau protein positron emission tomography (PET) tracers supporting the diagnosis and clinical management of Alzheimer’s disease and potential Tau-related disorders.

[Read More]

India’s Piramal to invest $1.5bn in biotech expansion

Monday, August 29, 2011

Piramal, the Indian conglomerate that recently invested $650m in Vodafone, plans to invest at least $1.5bn to expand aggressively its overseas pharmaceuticals business as it seeks to become the country’s first global drug developer, according to The Financial Times.

[Read More]